Regenerative Bio
Regenerative Bio uses artificial intelligence and cloud supercomputing to identify and develop therapies and formulations that target biological aging at the organ level. It applies organ-level aging clock technology within its RevOrgan platform to measure aging precisely and test intervention candidates. The company combines AI-driven pharmaceutical discovery methods with biology and cloud supercomputing to accelerate lead identification and formulation work. Regenerative Bio operates as an AI-driven biotechnology platform serving research and therapeutic development needs in the longevity sector.
Regenerative Bio
Regenerative Bio uses artificial intelligence and cloud supercomputing to identify and develop therapies and formulations that target biological aging at the organ level. It applies organ-level aging clock technology within its RevOrgan platform to measure aging precisely and test intervention candidates. The company combines AI-driven pharmaceutical discovery methods with biology and cloud supercomputing to accelerate lead identification and formulation work. Regenerative Bio operates as an AI-driven biotechnology platform serving research and therapeutic development needs in the longevity sector.
TL;DR
What they do: AI-driven biotech developing organ-level anti‑aging therapies and formulations using cloud supercomputing
Headquarters: Cambridge, Massachusetts, United States
Founded: 2021
Stage / funding: Angel round; multiple early investors
Team size: 11–50 employees (reported)
Company Overview
Problem Domain
Biological aging / longevity therapeutics; ingredient and formulation discovery
Founded
2021
Industry
Biotechnology
Tech Stack
Funding Track Record
10000000
Investor list also includes UpHonest Capital, Taihill Venture, K2VC, IMO Ventures
Investor Signal
“Multiple early-stage venture and angel investors including Yael Capital Management Limited and 5Y Capital”